OmniAb Resultados de beneficios anteriores
Pasado controles de criterios 0/6
Los beneficios de OmniAb han disminuido a una tasa media anual de -27.5%, mientras que en la industria Life Sciences los beneficios disminuyeron en un 2.1% anualmente. Los ingresos han ido disminuyendo a una tasa media de 11.6% al año.
Información clave
-27.50%
Tasa de crecimiento de los beneficios
-21.54%
Tasa de crecimiento del BPA
| Crecimiento de la industria Life Sciences | 21.51% |
| Tasa de crecimiento de los ingresos | -11.60% |
| Rentabilidad financiera | -24.26% |
| Margen neto | -347.04% |
| Próxima actualización de resultados | 07 May 2026 |
Actualizaciones de resultados anteriores recientes
Recent updates
OABI: Updated Bylaws And 2026 Guidance Will Support Long Term Upside
Analysts have nudged their OmniAb price target slightly higher to $170.16 from $162.92, reflecting updated assumptions around discount rates, revenue growth, profit margins and future P/E levels. What's in the News OmniAb issued earnings guidance for 2026, with expected revenue in a range of $25 million to $30 million.OABI: Updated Bylaws And 2026 Revenue Guidance Will Support Long Term Upside
Analysts kept their price target on OmniAb broadly aligned with prior views, citing relatively steady assumptions around fair value, growth and profitability that offset only minor tweaks to the discount rate and future P/E multiple. What's in the News OmniAb issued earnings guidance for 2026, with expected revenue in a range of $25 million to $30 million, giving you a reference point for the company’s own outlook on its top line for that year (Key Developments).OABI: Updated Governance And 2026 Revenue Outlook Will Support Long Term Upside
Analysts kept their fair value estimate for OmniAb steady at $7.33 while making only very small tweaks to assumptions such as discount rate, revenue growth, profit margin and future P/E. This reflects a largely unchanged view of the stock’s longer term risk and earnings potential.OABI: New Discovery Platform And Guidance Will Support Long Term Upside Potential
Analysts have modestly revised their price target on OmniAb, reflecting updated assumptions around long term revenue growth, profit margins, and future P/E expectations. Specific dollar values for the target change have not been disclosed.OABI: New Discovery Platform Will Support Stronger Long Term Upside Potential
Analysts have lowered their Omn iAb price target to $7.33 per share, citing slightly reduced profit margin assumptions and a modestly higher future P/E multiple, while keeping long-term revenue growth expectations broadly unchanged. What's in the News On January 30, 2026, OmniAb's board approved amended and restated bylaws that became effective the same day, updating the company’s governance framework.OABI: New Antibody Platform And Governance Changes Will Drive Future Upside
Analysts have modestly trimmed their price targets on OmniAb, citing slightly higher discount rate assumptions along with a small uplift in expected profit margins and future P/E levels as the key drivers of the recalibration. What's in the News On January 30, 2026, OmniAb's board approved amended and restated bylaws that took effect the same day, updating company rules and governance procedures.OABI: New Antibody Discovery Platform And Partnerships Will Drive Future Upside
Analysts have maintained their OmniAb price target at US$7.33, making only minor adjustments to assumptions such as the discount rate, long-term profit margin, and future P/E. These changes fine tune their valuation view rather than significantly revising it.OABI: New Antibody Platform Launch Will Drive Future Upside Potential
Analysts have lifted their price target on OmniAb to reflect updated assumptions for revenue growth of 41.53%, profit margin of 15.66% and a future P/E of 173.35x, which together suggest a slightly higher required return of 7.93% compared with prior inputs. What's in the News OmniAb launched its new OmniUltra platform at the 2025 Antibody Engineering & Therapeutics Conference in San Diego, describing it as a transgenic chicken system designed to generate human antibodies with ultralong CDRH3 domains and very small picobodies for a range of therapeutic uses, including bispecifics, multispecifics, CAR-T, radioligands and peptide therapeutics (Key Developments).OABI: Future Platform Launch And Partnerships Will Drive Revenue Upside
Narrative Update on OmniAb Analysts have maintained their price target on OmniAb at approximately 7.33 dollars, reflecting only marginal adjustments to the discount rate and profitability assumptions, while leaving their long-term growth outlook largely unchanged. What's in the News OmniAb plans to debut its new OmniUltra trademark transgenic chicken platform in December 2025 at the Antibody Engineering & Therapeutics conference.OABI: New Partnerships And Fundraising Will Support Revenue Expansion Ahead
OmniAb’s analyst price target remains unchanged at $7.33 per share. Analysts note that minor adjustments in profit margin and discount rate projections were not sufficient to alter their outlook on the company's value.OABI: Future Earnings and Margin Expansion Are Expected to Drive Share Upside
Analysts have lowered their price target for OmniAb from $7.86 to $7.33, citing updated expectations for higher revenue growth and profit margins. They also noted that an increased discount rate and a higher future price-to-earnings multiple were influencing factors.OmniAb, Inc. (NASDAQ:OABI) Not Lagging Industry On Growth Or Pricing
Oct 10
Analyst Estimates: Here's What Brokers Think Of OmniAb, Inc. (NASDAQ:OABI) After Its Second-Quarter Report
Aug 09Market Participants Recognise OmniAb, Inc.'s (NASDAQ:OABI) Revenues Pushing Shares 38% Higher
Jul 09OmniAb: Too Much Risk, Not Enough Reward
May 12Earnings Release: Here's Why Analysts Cut Their OmniAb, Inc. (NASDAQ:OABI) Price Target To US$7.88
May 11OmniAb, Inc. (NASDAQ:OABI) Shares Slammed 29% But Getting In Cheap Might Be Difficult Regardless
Apr 20
Novel Technologies And Clinical Pipeline Will Unlock Future Possibilities
Strong growth in partners and programs suggests robust future milestone and royalty revenues as technologies attract significant opportunities.OmniAb, Inc. (NASDAQ:OABI) Just Reported And Analysts Have Been Cutting Their Estimates
Nov 15Is OmniAb (NASDAQ:OABI) In A Good Position To Invest In Growth?
Sep 14Are Investors Undervaluing OmniAb, Inc. (NASDAQ:OABI) By 43%?
Jul 15The OmniAb, Inc. (NASDAQ:OABI) First-Quarter Results Are Out And Analysts Have Published New Forecasts
May 12Things Look Grim For OmniAb, Inc. (NASDAQ:OABI) After Today's Downgrade
Mar 26Revenues Not Telling The Story For OmniAb, Inc. (NASDAQ:OABI)
Feb 28OmniAb, Inc.'s (NASDAQ:OABI) Intrinsic Value Is Potentially 37% Above Its Share Price
Jan 15Unpleasant Surprises Could Be In Store For OmniAb, Inc.'s (NASDAQ:OABI) Shares
Nov 11Earnings Update: OmniAb, Inc. (NASDAQ:OABI) Just Reported And Analysts Are Trimming Their Forecasts
Aug 13OmniAb, Inc. (NASDAQ:OABI) Analysts Just Cut Their EPS Forecasts Substantially
May 14Desglose de ingresos y gastos
Cómo gana y gasta dinero OmniAb. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 31 Dec 25 | 19 | -65 | 34 | 40 |
| 30 Sep 25 | 21 | -64 | 35 | 42 |
| 30 Jun 25 | 23 | -64 | 35 | 45 |
| 31 Mar 25 | 27 | -61 | 35 | 48 |
| 31 Dec 24 | 26 | -62 | 36 | 50 |
| 30 Sep 24 | 20 | -63 | 33 | 55 |
| 30 Jun 24 | 22 | -62 | 37 | 52 |
| 31 Mar 24 | 21 | -63 | 38 | 53 |
| 31 Dec 23 | 34 | -51 | 38 | 52 |
| 30 Sep 23 | 65 | -30 | 39 | 51 |
| 30 Jun 23 | 66 | -27 | 37 | 50 |
| 31 Mar 23 | 66 | -22 | 33 | 47 |
| 31 Dec 22 | 59 | -22 | 29 | 44 |
| 30 Sep 22 | 39 | -32 | 25 | 40 |
| 30 Jun 22 | 38 | -28 | 19 | 41 |
| 31 Mar 22 | 38 | -25 | 19 | 39 |
| 31 Dec 21 | 35 | -27 | 19 | 37 |
| 30 Sep 21 | 33 | -24 | 16 | 36 |
| 31 Dec 20 | 23 | -18 | 10 | 25 |
| 31 Dec 19 | 18 | -14 | 9 | 13 |
Ingresos de calidad: OABI actualmente no es rentable.
Margen de beneficios creciente: OABI actualmente no es rentable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: OABI no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 27.5% al año.
Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de OABI en el último año con su promedio de 5 años, ya que actualmente no es rentable.
Beneficios vs. Industria: OABI no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Life Sciences (2.5%).
Rentabilidad financiera
Alta ROE: OABI tiene una rentabilidad financiera negativa (-24.26%), ya que actualmente no es rentable.
Rentabilidad económica
Rendimiento del capital invertido
Descubre empresas con buenos resultados en el pasado
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/03 07:29 |
| Precio de las acciones al final del día | 2026/05/01 00:00 |
| Beneficios | 2025/12/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
OmniAb, Inc. está cubierta por 9 analistas. 7 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Robert Wasserman | Benchmark Company |
| Matthew Hewitt | Craig-Hallum Capital Group LLC |
| Joseph Pantginis | H.C. Wainwright & Co. |